# Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy

> **NCT00655252** · — · NO_LONGER_AVAILABLE · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Metastatic Renal Cell Cancer

## Interventions

- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT00655252
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2011-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00655252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00655252, "Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00655252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*